Please assess the completion status of the following clinical trial:

Trial Title: Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic confirmation of NSCLC.~* Patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.~  * Unresectable phase IIIA(N2) and IIIB lung cancer confirmed by PET/CT, CT or MRI.~ * Whole lung V20\>=35% when giving 60Gy which is the minimum dose of radical irradiation.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.~* Previously treated with chemotherapy or treatment-naive~* No previous chest radiotherapy, immunotherapy or biotherapy~* Hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL~* Serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60 ml/min~* Bilirubin ≤1.5 times UNL, AST（SGOT）≤2.5 times UNL ,ALT（SGPT）≤2.5 times UNL,alkaline phosphatase ≤5 times UNL~* FEV1 \>0.8 L~* CB6 within normal limits~* patients and their family signed the informed consents~Exclusion Criteria:~* Previous or recent another malignancy, except nonmelanoma skin cancer or cervical cancer in situ~* Contraindication for chemotherapy~* Malignant pleural or pericardial effusion.~* Women in pregnancy, lactation period, or no pregnancy test 14 days before the first dose~* Women who has the probability of pregnancy without contraception~* Tendency of hemorrhage~* In other clinical trials within 30 days~* Addicted in drugs or alcohol, AIDS patients~* Uncontrollable seizure or psychotic patients without self-control ability~* Severe allergy or idiosyncrasy~* Not suitable for this study judged by researchers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone (Type: EXPERIMENTAL): Patients were treated with methylprednisolone after the first course of chest radiation and concurrent chemotherapy, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
- Observation (Type: ACTIVE_COMPARATOR): Observation after the first course of chest radiation, methylprednisolone can only be used for therapeutic purpose in the presence of grade≥2 radiation induced lung injury(NCI-CTC4.0).

Based on this trial design, predict the completion outcome and termination type (if applicable).